Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor β: a structure-based approach for cancer therapy

I. Habib, MN. Sulaimani, DS. Jairajpuri, A. Hussain, T. Mohammad, MF. Alajmi, A. Shamsi, MI. Hassan

. 2024 ; 11 (-) : 1492847. [pub] 20241015

Status not-indexed Language English Country Switzerland

Document type Journal Article

Platelet-derived growth factor receptor beta (PDGFRβ) belongs to the receptor tyrosine kinase (RTK) protein family and is implicated in several disorders such as hematopoietic, glial, and soft-tissue cancer, non-cancerous disorders, including skeletal defects, brain calcification, and vascular anomalies. The research on small molecule inhibitors targeting PDGFRβ in cancer treatment has seen promising developments, but significant gaps remain. PDGFRβ, receptor tyrosine kinase, is overexpressed in various cancers and plays an important role in tumor progression, making it a potential therapeutic target. However, despite advances in identifying and characterizing PDGFRβ inhibitors, few have progressed to clinical trials, and the mechanistic details of PDGFRβ's interactions with small molecule inhibitors are still not fully understood. Moreover, the specificity and selectivity of these inhibitors remain challenging, as off-target effects can lead to unwanted toxicity. In this investigation, two compounds, Genostrychnine and Chelidonine, were discovered that help inhibit the kinase activity of PDGFRβ. These small molecules were identified by employing various parameters involved in the drug discovery process, such as Lipinski's rule of five (RO5), 2D similarity search and 3D pharmacophore-based virtual screening followed by MD simulation studies. The identified molecules were found to be effective and significantly bound with the PDGFRβ kinase domain. Overall, our findings demonstrate that these small drug-like compounds can be beneficial tools in studying the properties of PDGFRβ and can play a crucial role in the therapeutic development of cancers and other associated diseases.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002353
003      
CZ-PrNML
005      
20250123101851.0
007      
ta
008      
250117e20241015sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmolb.2024.1492847 $2 doi
035    __
$a (PubMed)39473823
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Habib, Insan $u Department of Parasitology, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czechia $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
245    10
$a Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor β: a structure-based approach for cancer therapy / $c I. Habib, MN. Sulaimani, DS. Jairajpuri, A. Hussain, T. Mohammad, MF. Alajmi, A. Shamsi, MI. Hassan
520    9_
$a Platelet-derived growth factor receptor beta (PDGFRβ) belongs to the receptor tyrosine kinase (RTK) protein family and is implicated in several disorders such as hematopoietic, glial, and soft-tissue cancer, non-cancerous disorders, including skeletal defects, brain calcification, and vascular anomalies. The research on small molecule inhibitors targeting PDGFRβ in cancer treatment has seen promising developments, but significant gaps remain. PDGFRβ, receptor tyrosine kinase, is overexpressed in various cancers and plays an important role in tumor progression, making it a potential therapeutic target. However, despite advances in identifying and characterizing PDGFRβ inhibitors, few have progressed to clinical trials, and the mechanistic details of PDGFRβ's interactions with small molecule inhibitors are still not fully understood. Moreover, the specificity and selectivity of these inhibitors remain challenging, as off-target effects can lead to unwanted toxicity. In this investigation, two compounds, Genostrychnine and Chelidonine, were discovered that help inhibit the kinase activity of PDGFRβ. These small molecules were identified by employing various parameters involved in the drug discovery process, such as Lipinski's rule of five (RO5), 2D similarity search and 3D pharmacophore-based virtual screening followed by MD simulation studies. The identified molecules were found to be effective and significantly bound with the PDGFRβ kinase domain. Overall, our findings demonstrate that these small drug-like compounds can be beneficial tools in studying the properties of PDGFRβ and can play a crucial role in the therapeutic development of cancers and other associated diseases.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sulaimani, Md Nayab $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
700    1_
$a Jairajpuri, Deeba Shamim $u Department of Medical Biochemistry, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain
700    1_
$a Hussain, Afzal $u Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
700    1_
$a Mohammad, Taj $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
700    1_
$a Alajmi, Mohamed F $u Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
700    1_
$a Shamsi, Anas $u Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
700    1_
$a Hassan, Md Imtaiyaz $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
773    0_
$w MED00188065 $t Frontiers in molecular biosciences $x 2296-889X $g Roč. 11 (20241015), s. 1492847
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39473823 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101845 $b ABA008
999    __
$a ok $b bmc $g 2254549 $s 1238356
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 11 $c - $d 1492847 $e 20241015 $i 2296-889X $m Frontiers in molecular biosciences $n Front Mol Biosci $x MED00188065
LZP    __
$a Pubmed-20250117

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...